- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03273751
The Effect of Remote Ischemic Preconditioning on Kidney Function in Patients Undergoing Partial Nephrectomy
The Effect of Remote Ischemic Preconditioning on Kidney Function in Patients Undergoing Partial Nephrectomy : A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Remote Ischemic Preconditioning (RIPC) is the concept of mitigating ischemia-reperfusion injury to target organs by a brief episode of ischemia-reperfusion of the limb. The protective effect of RIPC on major organs has been demonstrated in an animal study, but its clinical efficacy has not yet been established.
The kidney is a typical organ vulnerable to ischemic injury, and the renal protective effect of RIPC can be expected. There have been many reports of renal protective effects of RIPC in cardiac and vascular surgery. On the other hand, few studies have investigated the effect of RIPC during partial nephrectomy in which ischemia-reperfusion injury can occur during the surgery.
In this study, the investigators will evaluate the effect of RIPC in patients undergoing partial nephrectomy to prevent renal impairment and improve the prognosis after the surgery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients scheduled to undergo open, laparoscopic, or robot-assisted laparoscopic partial nephrectomy
- Normal contralateral renal function was defined as split renal function of >40% as determined by preoperative Tc-99m DiethyleneTriamine Pentaacetic Acid (DTPA) kidney scan
- Written informed consent
Exclusion Criteria:
- Peripheral vascular disease involving upper extremities or lower extremities
- Severe cardiopulmonary diseases (valvular or ischemic heart disease, heart failure, chronic obstructive pulmonary disease)
- Hepatic failure, renal failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remote Ischemic Preconditioning (RIPC)
Four cycles of upper arm ischemia/reperfusion
|
After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Other Names:
|
Sham Comparator: Sham control
Placement of a blood pressure cuff around upper arm without inflation.
|
After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum creatinine level
Time Frame: Postoperative day 1
|
Postoperative serum creatinine levels as an index of kidney damage
|
Postoperative day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of acute kidney injury (AKI)
Time Frame: Within 7 days after surgery
|
The incidence of AKI according to the serum creatinine diagnostic criteria of Kidney Disease Improving Global outcomes (KDIGO) Clinical Practice Guideline for AKI
|
Within 7 days after surgery
|
Serum creatinine level
Time Frame: 1 hour after surgery
|
Postoperative serum creatinine levels as an index of kidney damage
|
1 hour after surgery
|
Serum creatinine level
Time Frame: Postoperative day 3
|
Postoperative serum creatinine levels as an index of kidney damage
|
Postoperative day 3
|
Serum creatinine level
Time Frame: 2 weeks after surgery
|
Postoperative serum creatinine levels as an index of kidney damage
|
2 weeks after surgery
|
estimated glomerular filtration rate (eGFR)
Time Frame: 1 hour after surgery
|
eGFR is obtained by the formula of Isotope Dilution Mass Spectrometry (IDMS) Modification of Diet in Renal Disease (MDRD).
|
1 hour after surgery
|
estimated glomerular filtration rate (eGFR)
Time Frame: Postoperative day 1
|
eGFR is obtained by the formula of Isotope Dilution Mass Spectrometry (IDMS) Modification of Diet in Renal Disease (MDRD).
|
Postoperative day 1
|
estimated glomerular filtration rate (eGFR)
Time Frame: Postoperative day 3
|
eGFR is obtained by the formula of Isotope Dilution Mass Spectrometry (IDMS) Modification of Diet in Renal Disease (MDRD).
|
Postoperative day 3
|
estimated glomerular filtration rate (eGFR)
Time Frame: 2 weeks after surgery
|
eGFR is obtained by the formula of Isotope Dilution Mass Spectrometry (IDMS) Modification of Diet in Renal Disease (MDRD).
|
2 weeks after surgery
|
Regional oxygen saturation (rSO2) of the contralateral kidney of the operated side
Time Frame: 5 min after the induction of anesthesia (baseline)
|
Renal rSO2 of the contralateral kidney of the operated side is monitored with Near-infrared spectroscopy.
|
5 min after the induction of anesthesia (baseline)
|
Regional oxygen saturation (rSO2) of the contralateral kidney of the operated side
Time Frame: 30 minutes after induction of anesthesia
|
Renal rSO2 of the contralateral kidney of the operated side is monitored with Near-infrared spectroscopy.
|
30 minutes after induction of anesthesia
|
Regional oxygen saturation (rSO2) of the contralateral kidney of the operated side
Time Frame: 60 minutes after induction of anesthesia
|
Renal rSO2 of the contralateral kidney of the operated side is monitored with Near-infrared spectroscopy.
|
60 minutes after induction of anesthesia
|
Regional oxygen saturation (rSO2) of the contralateral kidney of the operated side
Time Frame: 90 minutes after induction of anesthesia
|
Renal rSO2 of the contralateral kidney of the operated side is monitored with Near-infrared spectroscopy.
|
90 minutes after induction of anesthesia
|
Urine creatinine level
Time Frame: Postoperative day 1
|
Urine creatinine level
|
Postoperative day 1
|
Urine creatinine level
Time Frame: 2 weeks after surgery
|
Urine creatinine level
|
2 weeks after surgery
|
Urine microalbumin
Time Frame: Postoperative day 1
|
Urine microalbumin
|
Postoperative day 1
|
Urine microalbumin
Time Frame: 2 weeks after surgery
|
Urine microalbumin
|
2 weeks after surgery
|
Urine beta-2 microglobulin
Time Frame: Postoperative day 1
|
Urine beta-2 microglobulin
|
Postoperative day 1
|
Urine beta-2 microglobulin
Time Frame: 2 weeks after surgery
|
Urine beta-2 microglobulin
|
2 weeks after surgery
|
Urine N-acetyl-beta-D-glucosaminidase
Time Frame: Postoperative day 1
|
Urine N-acetyl-beta-D-glucosaminidase
|
Postoperative day 1
|
Urine N-acetyl-beta-D-glucosaminidase
Time Frame: 2 weeks after surgery
|
Urine N-acetyl-beta-D-glucosaminidase
|
2 weeks after surgery
|
Glomerular filtration rate measured by scintigraphy
Time Frame: preoperative baseline
|
Glomerular filtration rate measured by technetium diethylene triamine pentacetic acid (99mTc-DTPA) radionuclide scintigraphy
|
preoperative baseline
|
Glomerular filtration rate measured by scintigraphy
Time Frame: 6 months after surgery
|
Glomerular filtration rate measured by technetium diethylene triamine pentacetic acid (99mTc-DTPA) radionuclide scintigraphy
|
6 months after surgery
|
Glomerular filtration rate measured by scintigraphy
Time Frame: 12 months after surgery
|
Glomerular filtration rate measured by technetium diethylene triamine pentacetic acid (99mTc-DTPA) radionuclide scintigraphy
|
12 months after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Won Ho Kim, MD, PhD, Seoul National University Hospital
Publications and helpful links
General Publications
- Zarbock A, Schmidt C, Van Aken H, Wempe C, Martens S, Zahn PK, Wolf B, Goebel U, Schwer CI, Rosenberger P, Haeberle H, Gorlich D, Kellum JA, Meersch M; RenalRIPC Investigators. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA. 2015 Jun 2;313(21):2133-41. doi: 10.1001/jama.2015.4189.
- Huang J, Chen Y, Dong B, Kong W, Zhang J, Xue W, Liu D, Huang Y. Effect of remote ischaemic preconditioning on renal protection in patients undergoing laparoscopic partial nephrectomy: a 'blinded' randomised controlled trial. BJU Int. 2013 Jul;112(1):74-80. doi: 10.1111/bju.12004. Epub 2013 Mar 4.
- Zhang L, Diao Y, Chen G, Tanaka A, Eastwood GM, Bellomo R. Remote ischemic conditioning for kidney protection: A meta-analysis. J Crit Care. 2016 Jun;33:224-32. doi: 10.1016/j.jcrc.2016.01.026. Epub 2016 Feb 10.
- Hur M, Park SK, Shin J, Choi JY, Yoo S, Kim WH, Kim JT. The effect of remote ischemic preconditioning on serum creatinine in patients undergoing partial nephrectomy: a study protocol for a randomized controlled trial. Trials. 2018 Sep 4;19(1):473. doi: 10.1186/s13063-018-2820-3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1707-087-870
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Neoplasm
-
National Cancer Institute (NCI)RecruitingClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Soft Tissues | Metastatic Malignant Neoplasm in the Viscera and other conditionsUnited States, Puerto Rico
-
National Cancer Institute (NCI)Glaxosmithkline Biologicals S.A.TerminatedRenal Failure | Solid Neoplasm | BRAF Gene Mutation | Hepatic ComplicationUnited States, Canada
-
National Cancer Institute (NCI)Active, not recruitingClear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Locally Advanced Malignant Solid Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell CarcinomaUnited States
-
Novartis PharmaceuticalsTerminatedMetastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal FunctionBelgium
-
Novartis PharmaceuticalsTerminated
-
Aptose Biosciences Inc.University of Chicago; Wake Forest UniversityCompletedCarcinoma, Renal Cell | Metastases, NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Adult Solid NeoplasmUnited States
-
Massachusetts General HospitalPfizer; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical CenterCompletedRenal Cell Carcinoma | Neoplasm MetastasesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Janssen Research & Development, LLCActive, not recruitingClear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Bladder Urothelial Carcinoma | Metastatic Kidney Carcinoma | Malignant Urinary System NeoplasmUnited States
-
Genzyme, a Sanofi CompanyCompletedRenal Failure | Secondary Hyperparathyroidism | Chronic Renal InsufficiencyUnited States, Puerto Rico
Clinical Trials on Remote Ischemic Preconditioning
-
Tartu University HospitalCompletedAtherosclerosis | Stable Angina | Peripheral Artery Disease | Contrast-induced NephropathyEstonia
-
St. Francis Hospital, New YorkTerminatedCoronary Artery DiseaseUnited States
-
Capital Medical UniversityPeking University First HospitalCompletedCerebral Small Vessel DiseaseChina
-
Azienda Ospedaliera Città della Salute e della...CompletedAcute Kidney InjurySpain, France, Italy
-
Medical University of LodzCompletedRemote Ischemic Preconditioning | Contrast Induced - Acute Kidney InjuryPoland
-
Ulsan University HospitalCompletedContrast Induced Acute Kidney InjuryKorea, Republic of
-
Università Vita-Salute San RaffaeleRecruitingMyocardial Ischemia | SurgeryItaly, Russian Federation, Serbia
-
Institut für Pharmakologie und Präventive MedizinWithdrawnEffectivity of RIPC in Outcomes of TAVI ProcedureGermany
-
Xijing HospitalUnknownCardiac Surgery PatientsChina